145 related articles for article (PubMed ID: 30317296)
1. Diagnostic accuracy of glypican-3 in differentiating hepatocellular carcinoma from metastatic liver tumours.
Majeed S; Mushtaq S; Azam M; Akhtar N; Hussain M; Loya A
J Pak Med Assoc; 2018 Jul; 68(7):1029-1031. PubMed ID: 30317296
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.
Ibrahim TR; Abdel-Raouf SM
Pathol Oncol Res; 2015 Apr; 21(2):379-87. PubMed ID: 25108409
[TBL] [Abstract][Full Text] [Related]
3. Role of glypican-3 immunocytochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver utilizing fine needle aspiration cytology.
Zaakook M; Ayoub M; Sinna EA; El-Sheikh S
J Egypt Natl Canc Inst; 2013 Dec; 25(4):173-80. PubMed ID: 24207089
[TBL] [Abstract][Full Text] [Related]
4. [Significance of glypican-3 immunohistochemistry in diagnosis of hepatocellular carcinoma].
Yip YC; Wang FH; Vong HT; Zhang M; Wen JM
Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):626-9. PubMed ID: 22177248
[TBL] [Abstract][Full Text] [Related]
5. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.
Tremosini S; Forner A; Boix L; Vilana R; Bianchi L; Reig M; Rimola J; Rodríguez-Lope C; Ayuso C; Solé M; Bruix J
Gut; 2012 Oct; 61(10):1481-7. PubMed ID: 22287594
[TBL] [Abstract][Full Text] [Related]
6. A triple stain of reticulin, glypican-3, and glutamine synthetase: a useful aid in the diagnosis of liver lesions.
Swanson BJ; Yearsley MM; Marsh W; Frankel WL
Arch Pathol Lab Med; 2015 Apr; 139(4):537-42. PubMed ID: 25822763
[TBL] [Abstract][Full Text] [Related]
7. Hep par-1: a novel immunohistochemical marker for differentiating hepatocellular carcinoma from metastatic carcinoma.
Hanif R; Mansoor S
J Coll Physicians Surg Pak; 2014 Mar; 24(3):186-9. PubMed ID: 24613115
[TBL] [Abstract][Full Text] [Related]
8. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
9. Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study.
Ligato S; Mandich D; Cartun RW
Mod Pathol; 2008 May; 21(5):626-31. PubMed ID: 18264086
[TBL] [Abstract][Full Text] [Related]
10. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum.
Shafizadeh N; Ferrell LD; Kakar S
Mod Pathol; 2008 Aug; 21(8):1011-8. PubMed ID: 18536657
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM
Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547
[TBL] [Abstract][Full Text] [Related]
12. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
Nassar A; Cohen C; Siddiqui MT
Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
[TBL] [Abstract][Full Text] [Related]
13. The strength of cytomorphology and efficacy of immuno-cytochemistry in distinguishing hepatocellular carcinoma from its mimics on fine-needle aspiration cytology.
Chikhale M; Toi PC; Siddaraju N; Ananthakrishnan R
Diagn Cytopathol; 2021 Jul; 49(7):864-875. PubMed ID: 33929782
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value.
Wachter DL; Kristiansen G; Soll C; Hellerbrand C; Breuhahn K; Fritzsche F; Agaimy A; Hartmann A; Riener MO
Histopathology; 2012 Jan; 60(2):278-86. PubMed ID: 22211286
[TBL] [Abstract][Full Text] [Related]
15. [Significance of arginase-1, glypican-3, hepatocyte paraffin antigen 1 and alpha-fetoprotein in diagnosis and differential diagnosis of liver tumors].
Li J; Wei L
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):246-50. PubMed ID: 24915815
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3 is useful but not superior to Hep Par 1 in differentiating hepatocellular carcinoma from other liver tumours.
Pour AM; Masir N; Rose IM
Malays J Pathol; 2016 Dec; 38(3):229-233. PubMed ID: 28028292
[TBL] [Abstract][Full Text] [Related]
17. Quantification of glypican 3, β-catenin and claudin-1 protein expression in hepatoblastoma and paediatric hepatocellular carcinoma by colour deconvolution.
Zhou S; Parham DM; Yung E; Pattengale P; Wang L
Histopathology; 2015 Dec; 67(6):905-13. PubMed ID: 25939253
[TBL] [Abstract][Full Text] [Related]
18. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.
Yamauchi N; Watanabe A; Hishinuma M; Ohashi K; Midorikawa Y; Morishita Y; Niki T; Shibahara J; Mori M; Makuuchi M; Hippo Y; Kodama T; Iwanari H; Aburatani H; Fukayama M
Mod Pathol; 2005 Dec; 18(12):1591-8. PubMed ID: 15920546
[TBL] [Abstract][Full Text] [Related]
19. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma.
Yan B; Wei JJ; Qian YM; Zhao XL; Zhang WW; Xu AM; Zhang SH
Ann Diagn Pathol; 2011 Jun; 15(3):162-9. PubMed ID: 21371925
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma.
Jia X; Gao Y; Zhai D; Liu J; Cai J; Wang Y; Jing L; Du Z
Technol Cancer Res Treat; 2016 Dec; 15(6):780-786. PubMed ID: 26370140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]